This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists (DELAY)

This study has been completed.
Sponsor:
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
CMX Research
ClinicalTrials.gov Identifier:
NCT01366053
First received: May 30, 2011
Last updated: December 21, 2016
Last verified: December 2016
May 30, 2011
December 21, 2016
March 2011
July 2015   (Final data collection date for primary outcome measure)
Testosterone Suppression [ Time Frame: Two Years after first dose of degarelix. ]
To evaluate testosterone supression in hormone sensitive prostate cancer patients switched to Degarelix therapy after failing on GnRH agonists
Same as current
Complete list of historical versions of study NCT01366053 on ClinicalTrials.gov Archive Site
  • Hormone Levels [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate testosterone, bio available testosterone (calculated), prostate serum antigen (PSA), luteinizing hormone (LH) , follicle-stimulating hormone (FSH), dihydrotestosterone (DHT) and dehydroepiandrosterone (DHEA) before and after switching to Degarelix and over time
  • PSA Response [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate PSA response (ability of Degarelix to stabilise or reverse PSA progression)
  • PSA Failure [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate how long patients are on degeralix prior to demonstrating biochemical disease progression (time to PSA failure)
  • PSA Doubling Time [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate PSA doubling time.
  • Time to Metastases [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate how long patients are on degeralix before they develop metastases (non-metastatic patients)
  • Time to Chemotherapy [ Time Frame: Two Years after first dose of degarelix. ]
    Eevaluate how long patients have been on degeralix before initiating chemotherapy.
  • Time to Anti-Androgen use [ Time Frame: Two Years after first dose of degarelix. ]
    Evaluate how long patients are on degeralix before initiating anti-androgen use as well as response to anti-androgen use
  • Patient Performance Status [ Time Frame: Two Years after first dose of degarelix. ]
    To evaluate patient performance status as defined by the Eastern Cooperative Oncology Group (ECOG).
Same as current
Not Provided
Not Provided
 
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists
Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists: A Prospective, Observational, Phase IV Study (DELAY)

This Phase IV observational trial is intended to identify patients who are failing GnRH agonist therapy as evidenced by a rising PSA and who have yet to initiate secondary manoeuvres involving antiandrogens. This group may include both non-metastatic as well as metastatic patients. The trial will determine if these patients will benefit from switching to Degarelix. It will assess the effect of Degarelix's direct mode of action on androgen levels and whether continuous use of Degarelix improves disease progression.

As per the CUA Guidelines for the Management of CRPC, because the androgen receptor remains active in most patients who have developed castration resistant disease, it is recommended that ADT should be continued (LEVEL 3, GRADE C). Therefore, it is logical to continue patients on Degarelix throughout the castrate resistant period. This will allow for the gathering of data that is currently unknown within this setting, such as the effect of combined treatment with antiandrogens as well as chemotherapy and other castrate resistant treatments.

This trial will include hormone sensitive prostate cancer patients switched to Degarelix therapy after failing on GnRH agonists but prior to use of secondary hormonal treatments such as antiandrogens. The purpose of this trial is to determine the effect of Degarelix's direct mode of action on androgen levels and whether continuous use of Degarelix improves disease progression.

This is an open-label, multi-centre, Phase IV observational trial with s.c. injections of Degarelix one-month depot in patients with advanced prostate cancer.

The visit frequency is once a month (28-day intervals), with eCRF data entry at every 4 months. All patients will be treated with a one-month starting dose followed by 23 monthly maintenance doses for a duration of 672 days. The primary endpoints will be evaluated after 24 treatment months.

In total, 25 visits are scheduled for all patients.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with prostate cancer failing androgen deprivation therapy can be investigated in this trial.
Prostate Cancer
Not Provided
Prostate Cancer
Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
125
July 2015
July 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Able to read and write, understand instructions related to trial procedures and give written informed consent before any trial-related activity is performed
  • Histologically confirmed adenocarcinoma of the prostate (prostate cancer)
  • Currently under hormonal management of prostate cancer with a GnRH agonist
  • Confirmed biochemical PSA progression on GnRH agonist therapy, defined as ≥50% increase in PSA between 2 measurements, taken at least 1 week apart
  • PSA ≥1.0 ng/ml
  • ECOG score ≤2
  • Able and willing to participate in the full duration of the clinical trial
  • Male patient aged 18 years or older
  • Life expectancy of at least 12 months

Exclusion Criteria:

  • Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, ketoconazole or other secondary hormonal treatments such as antiandrogens except for induction phase (<3 months)
  • History of dermatitis, lupus, eczema, psoriasis affecting area used for Degarelix injections
  • Allergy to Degarelix or its components
  • Has a clinically significant disorder (other than prostate cancer) including, but not limited to, renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, which may affect the patient's health or the outcome of the trial as judged by the Investigator
  • Has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy.
  • Has a history of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema
  • Has a mental incapacity or language barrier precluding adequate understanding or co operation
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01366053
CMX-DELAY2010
No
Not Provided
Undecided
Not Provided
CMX Research
CMX Research
Ferring Pharmaceuticals
Principal Investigator: Richard Casey, M.D. CMX Research
Principal Investigator: Alvaro Morales, M.D. Queens University
CMX Research
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP